Información del producto
- (1R-trans)-N-[[2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
- Bms 214778
- Hetlioz
- N-[[(1R,2R)-2-(2,3-Dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
- N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
- Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]-
- Vec 162
- MA 1
Tasimelteon is a melatonin agonist that is used to treat insomnia in the elderly. It has been shown to be effective for the treatment of insomnia in geriatric patients with chronic liver impairment, who are unable to produce enough melatonin at night. Tasimelteon binds to melatonin receptors MT1 and MT2, which can be found throughout the body, including on cells of the immune system. As a result, tasimelteon may have an effect on autoimmune diseases by reducing inflammation. Tasimelteon has also been shown to increase the amount of light sensitivity in mice. This drug binds to the receptor site MT1 and MT2, leading to increased production of melatonin after exposure to bright light. The linear calibration curve was constructed using blood samples from healthy volunteers who were given tasimelteon before being exposed to bright light; it was found that tasimelteon led to higher concentrations of melatonin than would have occurred
Propiedades químicas
Consulta técnica sobre: 3D-JZA79922 Tasimelteon
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.